Cambridge Epigenetix has a vision to improve healthcare through routine measurement of the epigenome.
Location: United Kingdom, England, Cambridge
Employees: 51-200
Total raised: $144.5M
Founded date: 2012
Investors 5
| Date | Name | Website |
| - | Sequoia Ca... | sequoiacap... |
| - | Third Poin... | thirdpoint... |
| - | New Scienc... | newscience... |
| - | Ahren Inno... | ahreninnov... |
| - | GV | gv.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 02.11.2021 | Series D | $88M | - |
| 02.04.2018 | - | $30M | Ahren Inno... |
| 14.03.2016 | Series B | $21M | Illumina A... |
| 29.10.2014 | Series A | $5.5M | - |
Mentions in press and media 17
| Date | Title | Description |
| 03.11.2021 | Cambridge Epigenetix raises $88m Series D financing to advance DNA sequencing technology platform | Cambridge Epigenetix raises $88m Series D financing to advance DNA sequencing technology platform 03-11-2021 Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionising genome sequencing, has announced the sign... |
| 03.11.2021 | Cambridge Epigenetix raises $88m Series D financing to advance DNA sequencing technology platform | Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionising genome sequencing, has announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek le... |
| 02.11.2021 | Cambridge Epigenetix Raises $88 Million Series D Financing to Advance Best-in-Class DNA Sequencing Technology Platform | Technology increases the amount and quality of data that can be efficiently and cost-effectively obtained from a small DNA sample Manufacturing of the first product from a new technology platform is underway with expected commercial availab... |
| 02.11.2021 | Cambridge Epigenetix Raises $88 Million Series D Financing to Advance Best-in-Class DNA Sequencing Technology Platform | Technology increases the amount and quality of data that can be efficiently and cost-effectively obtained from a small DNA sample Manufacturing of the first product from a new technology platform is underway with expected commercial availab... |
| 03.09.2019 | Tom Hulme from GV is joining us at Disrupt Berlin | Based in London, Tom Hulme is a general partner for GV, the VC firm formerly known as Google Ventures. And Hulme isn’t your average VC, as he likes to focus on hard problems instead of quick wins. He has become an important figure of the Eu... |
| 02.04.2018 | Ahren Leads $30mn Funding Round in Cambridge Epigenetix | - |
| 30.03.2017 | SpyBiotech, which makes a ‘superglue’ for vaccines, raises £4M from GV and Oxford | The startup bug has hit the world of biotechnology, and the latest victim is a business that is building a “super glue,” coincidentally, for bug-combating vaccines. SpyBiotech — a startup spun out of Oxford University that has developed a w... |
| 17.03.2016 | Google’s GV leads $21M Series B in bioscience firm Cambridge Epigenetix | VC firm GV (née Google Ventures) has made another investment in Europe — its seventh — leading a $21 million Series B round for epigenetic sequencing tech company and Cambridge University spin-out, Cambridge Epigenetix. The U.K.-based biosc... |
| 14.03.2016 | Cambridge Epigenetix announces $21M Series B financing and appoints Dr Geoff Smith as CEO | Cambridge Epigenetix (CEGX), a pioneer in the development of epigenetic sequencing technologies, today announced the close of a $21 million Series B financing and the appointment of Dr. Geoff Smith as CEO. The round was led by GV (formerly ... |
| 14.03.2016 | Cambridge Epigenetix announces $21M Series B financing and appoints Dr Geoff Smith as CEO | Cambridge Epigenetix announces $21M Series B financing and appoints Dr Geoff Smith as CEO 14-03-2016 Cambridge Epigenetix (CEGX), a pioneer in the development of epigenetic sequencing technologies, today announced the close of a $21 million... |
Show more